Navigation Links
Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
Date:11/13/2012

THOUSAND OAKS, Calif. and BRYAN, Texas, November 13, 2012 /PRNewswire-iReach/ -- ImmunGene, Inc. (ImmunGene) and Caliber Biotherapeutics, LLC (Caliber) announced today the launch of Valor Biotherapeutics, LLC (Valor), a joint venture focused on the clinical development and commercialization of monoclonal antibody-interferon (mAb-IFN) fusion protein therapeutics targeting certain cancers.  The mAb-IFN fusion protein technology was invented in Professor Sherie Morrison's laboratory at the University of California, Los Angeles and licensed exclusively to ImmunGene.  This technology is being used to enable the precise targeting of tumor cells with monoclonal antibodies and their destruction by interferon.

(Photo: http://photos.prnewswire.com/prnh/20121113/CG09598)

Valor will combine the assets and resources of Caliber with ImmunGene's technologies, know-how, and intellectual property (IP).   ImmunGene will grant Valor exclusive licenses to its IP for three mAb-IFN fusion product candidates currently in various stages of preclinical development. Caliber will commit sufficient funds to enable Valor to reach certain development milestones for these compounds in the treatment of non-Hodgkin's lymphoma, multiple myeloma, and breast cancer.

Valor will be led by Rahul Singhvi, Sc.D., Managing Director of Caliber Biotherapeutics, LLC and former President and CEO of Novavax, Inc. Dr. Singhvi will be joined on the Valor board of directors by David Shanahan, a serial entrepreneur, philanthropist and a Caliber founder.  Mr. Shanahan is also the founder and President of Gradalis, Inc., a cancer immunotherapy company, and President of the Mary Crowley Cancer Research Center.  Dr. Sanjay Khare, CEO of ImmunGene, and Dr. Michael Gresser, Chair of ImmunGene's scientific advisory board, will also join the Valor board.

Dr. Singhvi commented, "The creation of Valor Biotherapeutics further marks the evolution of Caliber from a technology company into a drug development company with a highly promising pipeline.   We intend to leverage our complementary resources to develop these product candidates and welcome the opportunity to work with the highly accomplished ImmunGene team to accomplish our goals." 

"We are impressed with the promise of ImmunGene's mAb-IFN fusion technology in addressing many unmet needs in cancer," said Mr. Shanahan.  "We are thrilled to support the development of this technology through our joint venture and demonstrate the potential benefits this technology can bring to cancer patients."

"This joint venture will allow us to accelerate the development of ImmunGene's antibody interferon fusion drug candidates into human proof-of-concept studies in cancer patients." said Sanjay D. Khare, Ph.D., CEO of ImmunGene.  "We believe our technology has the potential to improve the treatment of certain cancers and that Caliber's unique experience in cancer research will help us realize the clinical and commercial potential of our pipeline through this promising joint venture." 

About Monoclonal Antibody – Interferon (mAb-IFN) Fusion Proteins

mAb-IFN fusion proteins are a new class of biotherapeutics that are produced by fusing antibodies to tumor cell-killing cytokines (e.g. IFN).  These fusion proteins offer potential advantages because several important properties can be built into a single, genetically engineered molecule.  They are thought to kill tumor cells mainly by stimulating apoptosis, in an ADCC (antibody-dependent cell-mediated cytotoxicity)-independent manner.  Consequently, these molecules have the potential to be efficacious in patients with defective ADCC mechanisms.  In addition, they have the potential to be cytotoxic to tumor cells with low density of targeted surface antigens.  The fusion proteins retain the properties of conventional, non-fused antibody therapeutics in stimulating ADCC and complement-dependent cytotoxicity (CDC) functions.  Such mAb-IFN fusion proteins have demonstrated superior efficacy and safety in preclinical studies, validating the therapeutic potential of this technology.

About ImmunGene Inc.

ImmunGene is a privately held biotechnology company focused on the development of monoclonal antibody-based therapies for the treatment of cancer. ImmunGene has several programs at various stages of the development. In addition, the company has developed proprietary antibody-cytokine fusion technology comprised of highly potent cytokines and stable linkers for genetically attaching the cytokines to monoclonal antibodies. ImmunGene has an exclusive license on the antibody-cytokine fusion protein technology developed by Professor Sherrie Morrison at UCLA.  More information can be found at: www.immungene.com.

About Caliber Biotherapeutics, LLC

Caliber Biotherapeutics, LLC is a biotechnology company based in Bryan, Texas with a mission to develop and commercialize protein-based therapeutics that improve outcomes for patients with cancer and other diseases. The Company utilizes technological innovations in biological research, product development and manufacturing to create treatments with increased safety and effectiveness--while reducing both costs and development time.  Caliber has created a rich pipeline of monoclonal antibody-based products, including biobetter product candidates applying its expertise in the Nicotiana benthamiana plant-based expression and manufacturing of recombinant proteins. Caliber operates the world's largest N. benthamiana expression based protein manufacturing facility in College Station, Texas. Caliber's technologies are being supported by the Cancer Prevention and Research Institution of Texas (CPRIT), DARPA and several Texas based life sciences investors.  For more information, please visit www.caliberbio.com.

Media Contact:

Rahul Singhvi Valor Biotherapeutics, 979-314-7740, info@valorbio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Valor Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Caliber IDs VivaScope technology found to be 100% sensitive for basal cell carcinoma diagnosis
2. Caliber Imaging & Diagnostics Releases New Products for Noninvasive, Rapid Imaging of Living Cells
3. Lucid, Inc. Reflects New Vision with Name Change to Caliber Imaging & Diagnostics, Inc.
4. AdvaMed Launches MVP Mentoring Portal for Veterans
5. SafeCode Drug Technologies Launches New Website With Product Video Demonstrating the Worlds Next Generation Application for Drug Safety Administration
6. AASLD Curriculum & Training (ACT) Launches With New Interactive HCV Education
7. Sarnova Launches Curaplex Private Label Brand
8. Zimmer Launches Smartphone Comeback App Globally
9. 3rd Annual National Event to Raise Awareness of Prescription Drug Abuse Launched
10. CVS/pharmacy to Launch Flu Shot Donation Campaign Benefiting the USO During Week of Veterans Day
11. QIAGEN Kicks Off Next-Generation Sequencing Initiative With Launch of a Series of Consumable Products to Improve NGS Workflows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Newly published research from ... Institute emphasizes the role a private retailer can play ... The study, published online today in the American ... decision to remove tobacco from all CVS Pharmacy stores ... settings with an even greater impact on those who ...
(Date:2/16/2017)... Summary Provides understanding and access to the allergy partnering ... ... Global Allergy Partnering Terms and Agreements since 2010 report provides understanding ... world,s leading healthcare companies. - Trends in partnering ... by company A-Z, industry sector, stage of development, technology type ...
(Date:2/16/2017)... Research and Markets has announced the addition of the ... Application, Cancer Type, Technology - Forecast to 2025" report to ... ... at a CAGR of around 28.6% over the next decade to ... of the prominent trends that the market is witnessing include increasing ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... While EHR data has revolutionized ... an innovative workstation designed to reduce nursing fatigue while enhancing productivity. Based on ... offers a lightweight, highly mobile, multi-functional alternative to the limitations of handheld computing. ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ET, http://www.fdanews.com/deviceapproval ... asking before selecting an FDA approval pathway? , How should they evaluate ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
(Date:2/17/2017)... ... 17, 2017 , ... PrideStaff, a national staffing organization, is ... Staffing Industry Analysts' 2017 "Staffing 100 North America" list. , Now in ... to the staffing industry over the last twelve months. Industry insiders and observers ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... services and financial planning assistance to families and business owners in and around ... a charity drive to help prevent all forms of domestic violence. , There ...
Breaking Medicine News(10 mins):